Respiratory delivery of 5-fluorouracil for the treatment of lung cancer

2005 2005

Other formats: Order a copy

Abstract (summary)

Lung cancer is the leading cause of cancer death in the U.S. in both men and women. While 5-fluorouracil (5-FU) is an effective chemotherapeutic agent, it is not used in lung cancer because of its high toxicity and unfavorable pharmacokinetics. Nevertheless, preliminary reports suggest inhalation of 5-FU is effective in the chemotherapy/chemoprevention of squamous cell carcinoma. In these studies, the delivery of 5-FU at a high dose/short duration is efficacious through incorporation into DNA and RNA. We postulated that 5-FU would also be effective if delivered by inhalation at a low dose/long duration through inhibition of DNA synthesis, while altering the type and severity of common side effects. To identify a delivery system to test this hypothesis, a microdialysis procedure was developed to evaluate the release of 5-FU from microcarriers that could be delivered to the lung by inhalation. Thereafter, drug release profiles were obtained from liposomes, microspheres and lipid coated nanoparticles (LNPs). The liposome systems released 5-FU in 6 hours or less, microsphere systems ranged from 6 to 30 hours, and LNPs ranged from 4 to 28 hours. Based on these results, a 600-nm diameter 5-FU/poly-(glutamic acid) core with a 200-nm thick tripalmitin/cetyl alcohol shell was chosen for further evaluation. An aerosol of LNPs was generated by ultrasonic nebulization coupled with an innovative reflux drying process, which is a time independent method that is ideal for aerosol exposure of large groups of rodents. The deposition and distribution of 5-FU from the microcarrier was determined in the Syrian Golden hamster model. The inhaled dose, 1.5 mg/kg 5-FU (30 mg LNPs/kg body weight), was delivered over an 8-minute interval. The concentration of LNPs and total 5-FU (released and LNP-associated) was determined as a function of time in the lung, trachea, larynx, esophagus, and serum. Within 24 hours, 99% of the LNPs were cleared from the respiratory tract. Total 5-FU concentrations mirrored the LNP concentration. An eight-compartment pharmacokinetic model was used to estimate the released 5-FU concentrations. From this analysis, effective local targeting as well as sustained efficacious concentrations of 5-FU in the expected tumor sites were demonstrated.

Indexing (details)

0572: Pharmaceuticals
0491: Pharmacology
0992: Oncology
Identifier / keyword
Health and environmental sciences; Pure sciences; Chemotherapy; Fluorouracil-5; Lung cancer; Respiratory delivery
Respiratory delivery of 5-fluorouracil for the treatment of lung cancer
Hitzman, Cory James
Number of pages
Publication year
Degree date
School code
DAI-B 66/11, Dissertation Abstracts International
Place of publication
Ann Arbor
Country of publication
United States
9780542386411, 0542386410
Wiedmann, Timothy Scott
University of Minnesota
University location
United States -- Minnesota
Source type
Dissertations & Theses
Document type
Dissertation/thesis number
ProQuest document ID
Database copyright ProQuest LLC; ProQuest does not claim copyright in the individual underlying works.
Document URL
Access the complete full text

You can get the full text of this document if it is part of your institution's ProQuest subscription.

Try one of the following:

  • Connect to ProQuest through your library network and search for the document from there.
  • Request the document from your library.
  • Go to the ProQuest login page and enter a ProQuest or My Research username / password.